Moderna has restarted its mRNA bird flu vaccine trial after securing international funding, while Amneal is betting big on the "golden era for biosimilars" with a $1.1 billion acquisition of Kashiv BioSciences. Meanwhile, Merck struck a $1 billion AI partnership with Google, and Sanofi's incoming CEO faces critical decisions about the company's immunology-focused R&D strategy as she takes over next week.
Top Stories
Moderna Rebounds to Launch Late-Stage mRNA Bird Flu Vaccine Trial After Losing U.S. Funding
After losing U.S. government support, Moderna has revived its bird flu vaccine program with backing from a public-private coalition and is now initiating a large late-stage trial that could support future regulatory approval, BioPharma Dive and STAT reported. The program had been caught in HHS's broader decision to abandon mRNA research but has been rescued by international funding partners. The company is continuing the study but with limited U.S. involvement. This signals that international health coalitions may increasingly fill gaps left by shifting U.S. policy priorities in pandemic preparedness.
Amneal Seizes 'Golden Era' for Biosimilars With $1.1B Kashiv BioSciences Acquisition
Amneal is acquiring biosimilars specialist Kashiv BioSciences for $1.1 billion, with co-CEO Chirag Patel declaring the industry has entered "the golden era for biosimilars," according to Fierce Pharma. The deal positions Amneal to capitalize on the wave of biologic patent expiries expected over the next several years and strengthens its position in the rapidly growing biosimilars market. Worth watching because this acquisition reflects broader industry confidence that biosimilars will finally achieve meaningful market penetration as payers and providers become more comfortable with switching.
Merck Strikes $1 Billion AI Partnership With Google in Enterprise Deal
Merck has inked an enterprise AI partnership with Google worth up to $1 billion, Fierce Pharma reports, as Big Pharma's embrace of artificial intelligence continues to accelerate amid broader industry restructuring. The deal represents one of the largest AI commitments by a pharmaceutical company to date and underscores the sector's belief that AI will transform drug discovery and development timelines. This move suggests pharma executives view AI infrastructure investments as essential competitive differentiators, not optional technology upgrades.
Sanofi's Incoming CEO Faces Critical Decision on Immunology-Focused R&D Strategy
As Belén Garijo prepares to take over as Sanofi CEO next week (week of April 27), she inherits a strategic crossroads created by outgoing CEO Paul Hudson's significant bet on immunology, Endpoints News reports. Garijo will need to decide whether to continue Hudson's immunology-focused wager or pivot the company's R&D strategy in a different direction. The decision comes as Sanofi's immunology pipeline faces heightened competitive pressure and as investors scrutinize returns on the substantial capital deployed in this therapeutic area. This signals a potential inflection point for one of the industry's largest players, with implications for therapeutic area priorities across the sector.
Eli Lilly Exits RIPK1 Space, Terminating Up to $960M Rigel Partnership
Eli Lilly has terminated the remainder of its up to $960 million partnership with Rigel Pharmaceuticals focused on RIPK1 inhibitors, joining a growing exodus of large drugmakers from this mechanism, according to Endpoints. The move reflects mounting skepticism about RIPK1 as a therapeutic target, with multiple major pharma companies now walking away from programs in this area. The trend suggests that early optimism about RIPK1's role in inflammatory and neurodegenerative diseases may have been overstated, raising questions about which other hot targets could face similar re-evaluation.
Nektar Therapeutics Prices $325M Public Offering to Fund General Corporate Purposes
Bay Area biotech Nektar Therapeutics has priced a $325 million public offering, selling approximately 3.5 million shares at $92 per share, with proceeds earmarked for general corporate purposes, Endpoints News reports. The substantial capital raise provides Nektar with financial runway as it advances its pipeline and navigates a challenging funding environment for biotech companies. This signals continued investor appetite for established biotechs with clinical-stage assets, even as early-stage companies face tighter capital markets.
Ray Therapeutics Secures $125M Series B for Vision Restoration Gene Therapy Pipeline
Ray Therapeutics has locked in $125 million in Series B funding backed by MSD and Novo Holdings to advance its vision restoration gene therapy pipeline for eye diseases, Pharmaceutical Technology reported. The substantial round will shed light on the potential of Ray's gene therapy platform targeting previously untreatable causes of blindness. Worth watching because ophthalmology gene therapies have faced commercial challenges despite clinical success, making Ray's approach and business model potentially instructive for the broader field.
What to Watch
- Sanofi Strategic Pivot — Garijo's first 90 days will likely reveal whether Sanofi doubles down on immunology or diversifies its R&D bet, with implications for therapeutic area investment across the industry.
- RIPK1 Mechanism Fallout — As multiple pharmas exit RIPK1 programs, watch for secondary effects on related inflammation targets and potential asset sales from affected biotechs.
- Biosimilar Market Dynamics — Amneal's billion-dollar Kashiv bet will test whether "golden era" rhetoric translates to actual market share gains against entrenched reference biologics.
- AI Infrastructure Arms Race — Merck's $1 billion Google partnership may trigger competitive responses from other pharmas seeking comparable cloud-based AI capabilities.
Market Snapshot
- CDMO Labor Tensions: Samsung Biologics' strike threat amid record revenues highlights how manufacturing capacity bottlenecks are empowering biopharma labor forces in key production hubs.
- Pandemic Preparedness Funding Shift: Moderna's pivot from U.S. to international funding for bird flu vaccines illustrates the rebalancing of global pandemic preparedness investment flows.
- Sovereign AI Competition: The UK's £500 million life sciences AI fund signals growing national competition for AI-enabled biotech leadership, potentially creating regional technology clusters.